LUTATHERA Injection General Use Result Survey
NCT05844332 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 347
Last updated 2025-12-22
Summary
This study was a multicenter observational study with a central registration system and all-case surveillance system without a control group.
Conditions
- Somatostatin Receptor-positive Neuroendocrine Tumor
Interventions
- OTHER
-
LUTATHERA
There was no treatment allocation. Patients administered LUTATHERA by prescription could be enrolled.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-17
- Primary Completion
- 2024-06-27
- Completion
- 2024-06-27
Countries
- Japan
Study Locations
More Related Trials
-
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
NCT02743741 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
NCT06395402 ·Status: RECRUITING ·Phase: PHASE2
-
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
NCT04609592 ·Status: RECRUITING ·Phase: PHASE1
-
An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours
NCT02236910 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
NCT05816720 ·Status: COMPLETED
-
Biomarker Identification of Radionuclide Therapy-induced Radiation Responses
NCT05513469 ·Status: UNKNOWN ·Phase: NA
-
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
NCT04837885 ·Status: RECRUITING ·Phase: PHASE2
-
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
NCT04919226 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
NCT02683941 ·Status: TERMINATED ·Phase: PHASE3
-
Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014
NCT01763554 ·Status: ACTIVE_NOT_RECRUITING
-
Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor
NCT03667092 ·Status: COMPLETED ·Phase: NA
-
177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
NCT03308682 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
NCT04614766 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
NCT01876771 ·Status: RECRUITING ·Phase: PHASE2
-
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
NCT05387603 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
NCT00326469 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients
NCT03422029 ·Status: UNKNOWN ·Phase: PHASE2
-
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression
NCT04029428 ·Status: UNKNOWN ·Phase: PHASE2
-
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
NCT04090034 ·Status: RECRUITING
-
Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients
NCT04917484 ·Status: RECRUITING ·Phase: PHASE2
-
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
NCT02231762 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
NCT03478358 ·Status: UNKNOWN ·Phase: PHASE1
-
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
NCT04665739 ·Status: RECRUITING ·Phase: PHASE2
-
Radiolabeled Molecules for Medullary Thyroid Cancer
NCT01915485 ·Status: UNKNOWN ·Phase: PHASE4
-
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
NCT01873248 ·Status: COMPLETED ·Phase: EARLY_PHASE1